Drugs / High-Dose Inactivated, Split-Virion Influenza Vaccine
High-Dose Inactivated, Split-Virion Influenza Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00391053 | Oct 2006 → Jul 2007 | influenza | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | High-Dose Inactivated, Split-Virion Influenza Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00391053 ↗ |
| Modality | Vaccine | “a high-dose (HD) trivalent, inactivated influenza vaccine was developed.” PMID 19508159 ↗ Jul 2009 |
| Route | Intramuscular | “0.5 mL, IM” NCT00391053 ↗ |